KCNN4 and non-small cell lung carcinoma: KCa3.1 overexpression could promote the pathogenesis of non-small cell lung cancer (NSCLC), while inhibition of KCa3.1 could suppress NSCLC via increasing ROS production and mitigating erlotinib resistance [226,227].